Psychedelic Business Spotlight: August 27, 2021
Delic establishes medical board to oversee psychedelic treatment protocols, cool new delivery systems investigated for psychedelics, and VR meets psychedelic therapies, finally.
Delic establishes medical board to oversee psychedelic treatment protocols, cool new delivery systems investigated for psychedelics, and VR meets psychedelic therapies, finally.
Clinicians are currently using TRIPP to help immerse patients into alternative realities and to support patients’ wellbeing before, during, and after ketamine-assisted therapy.
Although based in Canada, the company is building a clinical network of therapists trained in ketamine-assisted psychotherapy across the United States.
The clinics provide high-dose ketamine infusions, as well as intramuscular ketamine infusions for group therapy.
DMT treating eye disease? Psilocybin reducing obesity? The benefits of psychedelics could be truly far out as research continues to find novel applications.
“This designation not only expedites our regulatory, clinical, and product development plans but also validates our belief in the potential of ketamine,” says PharmaTher CEO Fabio Chianelli.
The Iranian model, actress and scientist bonds with former NBA star over spiritual experiences with deceased loved ones during psychedelic trips.
Study authors even believe “treating serious mental illness may reduce adverse outcomes related to COVID-19.”
The deal creates Wesana Clinics, a chain of mental health facilities focused on delivering psychedelic-assisted psychiatric care, as well as data platform Wesana Solutions.
This week in psychedelic business news: It’s all about partnerships and acquisitions designed to advance psychedelic therapies for depression, suicidal ideation, pain, and more.
End of content
End of content
By signing up to the Psychedelic Spotlight newsletter you agree to receive electronic communications from Psychedelic Spotlight that may sometimes include advertisements or sponsored content.